Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

What is Tilray Inc.?

Tilray Brands (NASDAQ: TLRY) is a cannabis company that operates in various sectors including cannabis, beverage, wellness, and distribution. The company recently reported record Q2 fiscal 2026 net revenue of $218 million and announced a transition to a net cash position.

Why is Tilray Inc. going down?

TLRY stock is down 5.3% on Jan 13, 2026 16:42

• Despite achieving record revenue and moving to a net cash position, Tilray's stock witnessed a notable bearish trend.
• The market reaction may have been influenced by a substantial EPS miss and deeply negative net margins, sparking investor concerns.
• Analysts recommending exploring alternative investment options despite increased positions from certain institutional investors might have exacerbated the bearish outlook.
• Ongoing worries surrounding operating losses, potential shareholder dilution, and the necessity for Tilray to capitalize on emerging market trends to enhance margins and cash flow likely played a role in the stock's bearish performance.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands (NASDAQ:TLRY) Shares Up 1.3% - Still a Buy?

Tilray Brands (NASDAQ:TLRY) shares increased by 1.3% during mid-day trading but analysts maintain a "Hold" rating with a target price of $20.00. The company recently reported a significant EPS miss with ($0.41) against estimates of ($0.14) and deeply negative net margins. Despite some institutional investors increasing their positions, analysts suggest considering other stocks for better investment opportunities.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-shares-up-13-still-a-buy-2026-01-12/

Should Tilray’s Record Q2 Revenue and THC Beverage Push Require Action From Tilray Brands (TLRY) Investors?

Tilray Brands recently reported record Q2 2026 revenue of US$217.51 million and a reduced net loss, while expanding its THC beverage portfolio with new hemp-derived cocktails and cannabis-infused drinks. This diversification into mindful and alcohol-free consumption is central to its strategy to achieve sustainable profitability, despite ongoing concerns about operating losses and potential shareholder dilution. The company's future hinges on its ability to leverage these new market trends to improve margins and cash flow.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/news/should-tilrays-record-q2-revenue-and-thc-beverage-push-requi

Tilray Brands Delivers Record Q2 Fiscal 2026 Net Revenue of $218 Million, Moves to Net Cash Position and Reaffirms Full-Year Adjusted EBITDA Guidance

Tilray Brands reported a record Q2 Fiscal 2026 net revenue of $218 million, an increase of 3% as a result of a 36% increase in international cannabis and a 6% increase in Canadian adult-use cannabis. The company also announced a transition to a net cash position and reaffirmed its full-year Adjusted EBITDA guidance of $62 million to $72 million. These results reflect disciplined execution across its diversified portfolio, with strong performance in international medical cannabis and distribution, alongside a strengthened balance sheet.

https://www.globenewswire.com/news-release/2026/01/08/3215788/0/en/Tilray-Brands-Delivers-Record-Q2-Fiscal-2026-Net-Revenue-of-218-Million-Moves-to-Net-Cash-Position-and-Reaffirms-Full-Year-Adjusted-EBITDA-Guidance.html

Tilray Earnings: Decent Results Support Our View That Recent Share Plunge Was Overdone

Tilray Brands (TLRY) reported fiscal second-quarter 2026 net revenue growth of 3% to $218 million, driven by strong performance in cannabis and distribution segments, despite a decline in beverages. Morningstar maintains its $14 per share fair value estimate, considering Tilray's stock undervalued due to underestimation of its profit growth potential in Canadian and international cannabis markets. The recent share plunge was likely overdone, as the company's results align with Morningstar’s view of its market positioning and future prospects.

https://www.morningstar.com/stocks/tilray-earnings-decent-results-support-our-view-that-recent-share-plunge-was-overdone

Tilray Brands Delivers Record Quarterly Net Revenue of $218M

Tilray Brands Inc. reported a record quarterly net revenue of $218 million for its second fiscal quarter ended November 30, 2025, driven by diversified growth across its cannabis, beverage, wellness, and distribution sectors. The company achieved a net cash positive position and reaffirmed its fiscal year 2026 adjusted EBITDA guidance of $62 million to $72 million. Tilray also highlighted its preparedness to leverage its medical cannabis infrastructure in the event of federal rescheduling in the U.S.

https://www.cannabisbusinesstimes.com/finance/news/15814250/tilray-brands-delivers-record-quarterly-net-revenue-of-218m

Trending Today

Apache Corporation ($APA) Stock Forecast: Up 5.1% Today

Dow Inc. ($DOW) Stock Forecast: Up 6.3% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Down 5.8% Today

ConocoPhillips ($COP) Stock Forecast: Up 5.4% Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 5.1% Today

Devon Energy Corporation ($DVN) Stock Forecast: Up 5.1% Today

Peabody Energy Corporation ($BTU) Stock Forecast: Up 5.4% Today

Intuit Inc. ($INTU) Stock Forecast: Down 7.4% Today

BlackLine, Inc. ($BL) Stock Forecast: Down 5.2% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Up 5.3% Today

Tilray Inc. Price History

13.00.2026 - TLRY Stock was down 5.3%

• Despite achieving record revenue and moving to a net cash position, Tilray's stock witnessed a notable bearish trend.
• The market reaction may have been influenced by a substantial EPS miss and deeply negative net margins, sparking investor concerns.
• Analysts recommending exploring alternative investment options despite increased positions from certain institutional investors might have exacerbated the bearish outlook.
• Ongoing worries surrounding operating losses, potential shareholder dilution, and the necessity for Tilray to capitalize on emerging market trends to enhance margins and cash flow likely played a role in the stock's bearish performance.

22.11.2025 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today could be attributed to the company's ongoing financial struggles, lack of earnings, and cash burn.
• Despite recent positive sentiment and stock rises driven by potential easing of marijuana restrictions and strategic developments, the market may be reacting to the underlying financial challenges faced by Tilray.
• The uncertainty surrounding U.S. marijuana reform, particularly the reliance on federal rescheduling rather than outright legalization, might be causing investors to exercise caution and reevaluate their positions in Tilray.

22.11.2025 - TLRY Stock was down 6.0%

• The bearish movement in TLRY stock today could be attributed to the anticipation and uncertainty surrounding the upcoming financial results announcement.
• Comments on Tilray's lack of earnings may have contributed to investor skepticism and selling pressure on the stock.
• Despite the positive news about Tilray's formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations, the overall market sentiment may have been overshadowed by concerns about the company's financial performance and growth strategy.
• The market might be reacting to the realization that Tilray's growth is primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment, raising doubts about the company's long-term sustainability.

19.11.2025 - TLRY Stock was down 8.4%

• There was a significant bearish movement in TLRY stock today, possibly due to investors cashing out profits following a recent surge triggered by indications of potential marijuana reclassification by a former President.
• Market reaction may be influenced by experts warning that moving cannabis to Schedule III doesn't mean federal legalization, causing uncertainty and prompting selling.
• Despite forming Tilray Medical USA, Inc. to expand U.S. medical cannabis operations, the company's financial difficulties, ongoing losses, and focus on alcohol acquisitions rather than cannabis growth could be fueling negative market sentiment.
• The uncertain regulatory landscape for cannabis, paired with a recent reverse split and general market instability, may be intensifying downward pressure on Tilray's stock price.

12.00.2026 - TLRY Stock was up 4.9%

• Reported a record Q2 Fiscal 2026 net revenue of $218 million, led by strong performance in international cannabis and Canadian adult-use cannabis segments.
• Transitioned to a net cash position and reaffirmed full-year Adjusted EBITDA guidance, highlighting disciplined execution and a strengthened balance sheet.
• Analysts' opinion that the recent share plunge was overdone aligns with financial results, suggesting potential undervaluation due to underestimation of profit growth in Canadian and international cannabis markets.
• Strategic expansion into the beverage segment, along with readiness to leverage medical cannabis infrastructure in the U.S., positions the company for future growth amidst potential regulatory shifts in the cannabis market.

24.11.2025 - TLRY Stock was down 5.3%

• The upcoming announcement of Tilray Brands' second fiscal quarter financial results has likely created uncertainty and caution among investors, leading to a sell-off of the stock.
• Despite the recent drop, the stock has shown a notable increase over the past month, indicating potential profit-taking by traders.
• The lack of substantial analysis suggests a disconnect between market sentiment and speculative opinions on whether the stock's fall presents a buying opportunity.
• Investors are eagerly awaiting the earnings report, with expectations of a significant increase in EPS, but a slight decrease in revenue compared to the previous year, adding to the volatility surrounding the stock.

06.00.2026 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today can be attributed to multiple factors:
• The formation of a bearish head-and-shoulders pattern, indicating a potential trend reversal and investor caution.
• Heightened volatility ahead of the earnings release, with analysts expecting significant price swings and a projected loss per share.
• The company's expansion into non-alcoholic, cannabis-infused beverages for its "Dry January" campaign might not have been well-received by investors, impacting the stock negatively.
• Investors are closely monitoring Tilray's financial results release on January 9th, potential cannabis reclassification efforts in the US, and the impact of increased competition in the US market for further insights into the stock's performance.

17.11.2025 - TLRY Stock was down 8.1%

• Despite positive developments regarding the potential reclassification of marijuana from Schedule I to Schedule III, Tilray faced a bearish movement.
• The surge in Tilray's stock price post speculations on marijuana reclassification by Trump might have prompted profit-taking actions among investors, leading to the bearish movement.
• Uncertainty surrounding the final reclassification decision and profit-taking activities likely contributed to Tilray's stock price decline today.
• The market sentiment towards Tilray remains optimistic, anticipating future ease in federal restrictions and potential improvements in profitability.

02.00.2026 - TLRY Stock was up 5.6%

• Tilray's stock is struggling to maintain momentum despite recent U.S. regulatory shifts and political support, trading below key technical levels.
• Investor focus is on the upcoming Q2 earnings report, with expectations of a loss per share on revenue. Analysts are looking for signs of financial progress from cost-saving measures and brand integrations.
• The stock's increased attention on social media platforms is sparking discussions about whether TLRY's current mid-single digit trading price reflects a genuine recovery or speculative hype.
• Analysts have a cautiously optimistic stance, considering potential U.S. policy changes and growth in Tilray's alcohol business, balanced against risks like weak cannabis sales and ongoing losses.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock price decreased by 4.2%, closing at $10.085, which was below the broader market performance.
• Analysts have given a consensus "Hold" rating with an average price target of $20, showing caution among investors.
• The drop in stock price may be linked to lower-than-expected performance and uncertainties about the upcoming second fiscal quarter results.
• Despite optimistic prospects for potential cannabis rescheduling and hemp-derived products, investors might be hesitant due to recent underperformance and competition in the AI sector.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock experienced a 4.2% decline in value during mid-day trading, closing at $10.085.
• Analysts have assigned a consensus "Hold" rating to Tilray, with a median price target of $20, indicating a potential upside of 88.49%.
• The bearish movement could be attributed to the cautious sentiment among analysts, despite potential positive developments such as cannabis rescheduling and revised product definitions.
• The upcoming announcement of Tilray's second fiscal quarter results may also be contributing to investor uncertainty and selling pressure on the stock.

19.11.2025 - TLRY Stock was down 23.1%

• Today's bearish movement in TLRY may be due to investors taking profits following a recent surge influenced by discussions of President Trump contemplating cannabis reclassification.
• Though there is optimism about regulatory changes, the speculative nature of the cannabis industry and uncertainties regarding federal legalization may be causing some traders to proceed with caution.
• Volatility in TLRY's stock price could be impacted by option traders anticipating significant year-end movements, leading to short-term market fluctuations.
• It is important for investors to stay informed about any official announcements on cannabis regulations to navigate the current market volatility effectively.